Table 1.
Clinical and Histopathological Characteristics of the Patients (n = 166)
| Features | n = 166 (%) |
|---|---|
| Age (years) | Median: 54 (Range:28–87) |
| <40 | 20 (12) |
| 40–49 | 45 (27.1) |
| 50–59 | 38 (22.9) |
| 60–64 | 24 (14.5) |
| >65 | 39 (23.5) |
| Tumor Grade | |
| I | 15 (9) |
| II | 97 (58.4) |
| III | 54 (32.5) |
| Tumor Size (cm) | |
| T1 | 20 (12) |
| T2 | 86 (51.8) |
| T3 | 37 (22.3) |
| T4 | 23 (13.9) |
| Axillary Lymph Node Status | |
| N0 | 89 (53.6) |
| N1 | 43 (25.9) |
| N2 | 17 (10.2) |
| N3 | 17 (10.2) |
| TNM Stage | |
| I | 27 (16.3) |
| II | 94 (56.6) |
| III | 45 (27.1) |
| Estrogen Receptor Expression | |
| Positive | 100(60.2) |
| Negative | 66 (39.8) |
| Progesterone Receptor Expression | |
| Positive | 87 (52.4) |
| Negative | 79 (47.6) |
| HER-2/neu Expression | |
| Positive | 50 (30.1) |
| Negative | 116 (69.9) |
| Androgen Receptor Expression | |
| Positive | 104 (62.7) |
| Negative | 62 (37.3) |
| CD44 Expression | |
| Positive | 102 (61.4) |
| Negative | 64 (38.6) |
| CD24 Expression | |
| Positive | 73 (44) |
| Negative | 93 (56) |
| ALDH1 Expression | |
| Positive | 50 (30.1) |
| Negative | 116 (69.9) |